



## EHA RESEARCH GRANT AGREEMENT

### EHA Executive Office

Koninginnegracht 12b  
2514 AA The Hague  
The Netherlands

+31 (0)70 3020 099  
info@ehaweb.org

This EHA Physician Scientist Research Grant Agreement ("**Agreement**") is made and entered into by and between:

### UNDERSIGNED:

**European Hematology Association**, an association under the laws of the Netherlands, registered under trade registry number 24334797, with its address at Koninginnegracht 12b, 2514 AA - The Hague, The Netherlands ("**EHA**");

### AND

**Tomas Jelinek**, University of Ostrava, Faculty of Medicine, Department of Hematooncology, Dvořákova 7, 701 03 Ostrava, Czechia ("**Grantee**");

### AND

**University of Ostrava**, Faculty of Medicine, Department of Hematooncology, Dvořákova 7, 701 03 Ostrava, Czechia ("**Grantee Institute**").

Individually referred to as a "**Party**" and collectively as the "**Parties**".

By applying for an EHA Physician Scientist Research Grant, the applicants and their institutes acknowledge and accept the conditions as set out in this Agreement.

### AGREED TERMS:

#### ARTICLE 1. 'Grant and Purpose'

EHA awards a Physician Scientist Research Grant of € 239,130 (Euros) to support the project "Tumor microenvironment and clonal evolution in myeloma extramedullary disease" ("**Project**"), to be executed from 01 September 2025 to 31 August 2028. The grant funds shall be used solely in accordance with the approved budget and proposal ("**Annex 1**").

#### ARTICLE 2. 'Financial Terms'

- a. Grant funds will be transferred to the Grantee Institute, not to a personal account, according to the payment schedule ("**Annex 2**"), contingent on receipt and approval of the interim and final reports ("**Annex 3**").
- b. EHA will not fund overhead costs.
- c. Any unused or misused funds must be returned to EHA upon request.
- d. A separate account must be maintained for grant funds.
- e. The Grantee and Grantee Institute shall notify EHA within thirty (30) days upon securing any additional project-related funding, including a statement describing its expected impact on the approved Project budget.



- f. Under no circumstance may costs related to the Project be reimbursed or charged more than once, including from EHA and/or other funding resources.

### **ARTICLE 3. 'Reporting'**

- a. Interim and final scientific reports and financial statements must be submitted according to the templates provided by EHA and on dates specified on the reporting schedule ("**Annex 3**").
- b. Interim and final financial statements must be signed by a finance officer at the Grantee Institute. The final financial statement must include an audited accounting signed off by an independent external auditor. The Grantee should reserve up to € 2,000 (Euros) in the Project budget for this purpose.
- c. The Grantee agrees to submit annual impact reports to EHA's impact measurement platform (e.g., Researchfish/Elsevier) during the grant period and for up to five (5) years following the end of the grant, and thereafter upon EHA's request.
- d. EHA may request interim updates during or after the Project for impact monitoring.
- e. EHA reserves the right to review or audit the use of grant funds at any time during or within two years after the Project period.
- f. The Grantee Institute shall retain all financial and project-related records for a period of at least five years after the end of the Project period and make them available to EHA upon request.

### **ARTICLE 4. 'Amendments'**

Changes to the Project, including extensions, budget reallocations or institution changes, require prior written approval from EHA via an amendment request submitted at least 30 days in advance. Unapproved changes may lead to repayment obligations.

### **ARTICLE 5. 'Acknowledgment and Publicity'**

All Project outputs must acknowledge EHA support:

"Funding for this project was provided by an EHA Physician Scientist Research Grant awarded by the European Hematology Association."

Public announcements require prior approval from EHA. The Grantee agrees to cooperate in public visibility efforts. The Grantee shall not use EHA's name, logo, or other trademarks in any communication, including but not limited to press release, websites or promotional materials, without EHA's prior written approval.

### **ARTICLE 6. 'Conduct and Compliance'**

The Grantee Institute ensures that the Project complies with all applicable laws, ethics approvals, and safety regulations. The Grantee and Grantee Institute bear sole responsibility for research conduct.

### **ARTICLE 7. 'Data Protection'**

All Parties shall comply with applicable data protection laws, including the GDPR. Each Party is an independent data controller and shall maintain confidentiality of shared personal data. Data breaches must be reported without undue delay.

**ARTICLE 8. 'Independent Status'**

This Agreement does not create an employment, agency or joint venture relationship. Each Party remains fully independent and responsible for its obligations.

**ARTICLE 9. 'Liability'**

EHA is not liable for damages except in case of gross negligence or wilful misconduct by EHA's management. The Grantee and Grantee Institute shall indemnify EHA against third-party claims arising from the Project. EHA shall not be liable for any taxes, social security contributions, or other financial obligations arising from the grant.

**ARTICLE 10. 'Confidentiality'**

All Parties agree to keep confidential any non-public information obtained in connection with this Agreement, unless disclosure is required by law or with prior written consent of the other Party.

**ARTICLE 11. 'Termination'**

EHA may terminate this Agreement with immediate effect if:

- a. the Project is discontinued or materially altered without approval;
- b. misconduct, fraud or insolvency occurs;
- c. the Grantee and/ or Grantee Institute breach this Agreement;
- d. EHA becomes reasonably unable to make further payments for financial or organizational reasons.

Upon termination, EHA may require full or partial repayment. Termination does not affect obligations relating to reporting, confidentiality, data protection, or liability, which shall survive termination.

**ARTICLE 12. 'Governing Law'**

This Agreement is governed by Dutch law. All disputes shall be resolved exclusively by the District Court of The Hague, the Netherlands.

This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but such counterparts shall together constitute one and the same document.



European  
Hematology  
Association

IN WITNESS WHEREOF:

The Parties hereto have executed this Agreement

for and on behalf of  
**EUROPEAN HEMATOLOGY  
ASSOCIATION**

**GRANTEE**

for and on behalf of  
**GRANTEE  
INSTITUTE**

*Ignacio Quiles Lara*

By: Ignacio Quiles Lara  
Position: EHA Managing Director  
Date: 2025/08/11

*Tomas Jelinek*

Name: Tomas Jelinek  
Position: Physician Scientist  
Date: 2025/08/06

*Petr Kopecký*

Name: Petr Kopecký  
Position: Rector  
Date: 2025/08/11


**ANNEX 1. 'Budget and proposal'**

Approved budget and proposal submitted via the application platform (Fluxx).

**ANNEX 2. 'Financial Terms'**

EHA will fund a maximum Physician Scientist Research Grant of € 239,130 (Euros). EHA will disburse grant funds according to the following schedule, contingent on receipt and approval of the interim and final reports mentioned in **Annex 3**.

Amount in € (Euros)	Due On or About
€ 108,000	28 August 2025
€ 108,000	08 April 2027
€ 23,130	16 November 2028

The grant will be transferred to the following bank account of the Grantee Institute:

Bank name	Česká národní banka (ČNB)
Bank address	pobočka Ostrava, Nádražní 4, 701 01 Ostrava 1
Account number	94-931761/0710
Name account holder	University of Ostrava
Address account holder	Dvorakova 7, Ostrava, 701 03, VAT: CZ61988987
IBAN	CZ65 0710 0000 0000 0093 1761
SWIFT	CNBACZPP
Reference code or number	

All expenditures of grant funds by the Grantee and/or Grantee Institute must be spent within the Project period and must be consistent with the Project budget, as set forth in the approved proposal (**Annex 1**). EHA will not be responsible for any other fees, costs or expenses.

**ANNEX 3. 'Reporting'**

The Grantee and Grantee Institute agree to deliver to the Grants Manager at EHA detailed Project status and expenditure reports according to templates provided by EHA and on dates specified in the following schedule.

REPORTS	DUE DATE
Interim Scientific Report and Financial Statement	01 March 2027
Final Scientific Report, Financial Statement and Audit Report	12 October 2028

## Certificate Of Completion

Envelope Id: D2CEAE59-7279-4D3B-9DAA-8D02180FA1AF

Subject: Complete with Docusign: EHA\_Draft\_Grant Agreement\_Tomas Jelinek\_PSRG\_2025.pdf

Source Envelope:

Document Pages: 5

Signatures: 3

Certificate Pages: 5

Initials: 0

AutoNav: Enabled

Envelopeld Stamping: Enabled

Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

Status: Completed

Envelope Originator:

Research

Koninginnegracht 12b/13

The Hague, South Holland 2514 AA

research@ehaweb.org

IP Address: 212.98.232.211

## Record Tracking

Status: Original

8/6/2025 9:32:01 AM

Holder: Research

research@ehaweb.org

Location: DocuSign

## Signer Events

Tomas Jelinek

tomas.jelinek.md@gmail.com

Physician Scientist

Security Level: Email, Account Authentication  
(None)

## Signature

Signature Adoption: Pre-selected Style

Using IP Address: 93.95.33.131

## Timestamp

Sent: 8/6/2025 9:35:44 AM

Viewed: 8/6/2025 11:45:23 AM

Signed: 8/6/2025 12:42:34 PM

## Electronic Record and Signature Disclosure:

Accepted: 8/6/2025 11:45:23 AM

ID: 03641394-cf73-44f3-9c46-b6cdf3d26650

Company Name: European Hematology Association

Petr Kopecký

Rektor@osu.cz

Security Level: Email, Account Authentication  
(None)

Signature Adoption: Pre-selected Style

Using IP Address: 2001:718:1005:107::1a1e

Sent: 8/6/2025 12:42:35 PM

Resent: 8/11/2025 11:48:42 AM

Viewed: 8/11/2025 12:18:12 PM

Signed: 8/11/2025 12:19:10 PM

## Electronic Record and Signature Disclosure:

Accepted: 8/11/2025 12:18:12 PM

ID: b00e9908-d8ad-4519-b6d3-00d4afc8659f

Company Name: European Hematology Association

Ignacio Quiles Lara

i.quiles@ehaweb.org

Managing Director

EHA

Security Level: Email, Account Authentication  
(None)

Signature Adoption: Pre-selected Style

Using IP Address: 181.171.121.206

Signed using mobile

Sent: 8/11/2025 12:19:11 PM

Viewed: 8/11/2025 1:23:51 PM

Signed: 8/11/2025 1:24:01 PM

## Electronic Record and Signature Disclosure:

Accepted: 8/11/2025 1:23:51 PM

ID: f314ba0e-0b01-43b5-bc51-fc3c5c0feacf

Company Name: European Hematology Association

## In Person Signer Events

## Signature

## Timestamp

## Editor Delivery Events

## Status

## Timestamp

## Agent Delivery Events

## Status

## Timestamp

## Intermediary Delivery Events

## Status

## Timestamp

Certified Delivery Events	Status	Timestamp
---------------------------	--------	-----------

Carbon Copy Events	Status	Timestamp
--------------------	--------	-----------

Grants office grants@ehaweb.org Security Level: Email, Account Authentication (None) <b>Electronic Record and Signature Disclosure:</b> Not Offered via DocuSign	<div>COPIED</div>	Sent: 8/11/2025 1:24:02 PM
--	-------------------	----------------------------

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
-------------------------	--------	------------

Envelope Sent	Hashed/Encrypted	8/6/2025 9:35:44 AM
Envelope Updated	Security Checked	8/11/2025 11:48:41 AM
Certified Delivered	Security Checked	8/11/2025 1:23:51 PM
Signing Complete	Security Checked	8/11/2025 1:24:01 PM
Completed	Security Checked	8/11/2025 1:24:02 PM

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, European Hematology Association (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact European Hematology Association:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [officemanagement@ehaweb.org](mailto:officemanagement@ehaweb.org)

### **To advise European Hematology Association of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [officemanagement@ehaweb.org](mailto:officemanagement@ehaweb.org) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from European Hematology Association**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [officemanagement@ehaweb.org](mailto:officemanagement@ehaweb.org) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with European Hematology Association**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [officemanagement@ehaweb.org](mailto:officemanagement@ehaweb.org) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify European Hematology Association as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by European Hematology Association during the course of your relationship with European Hematology Association.